Noven signs agreements with P&G Pharmaceuticals for patches to treat HSDD

Noven Pharmaceuticals has agreed a global license and supply deal with Procter & Gamble Pharmaceuticals (P&GP), a subsidiary of The Procter & Gamble Co, for the development and commercialisation of prescription transdermal patches for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in women.

Noven has granted P&GP an exclusive worldwide license to a testosterone patch for the treatment of HSDD in women, as well as potential next-generation patches in the same therapeutic category. The agreements provide for payment to Noven of royalties and manufacturing fees, as well as development and sales milestones, relating to the licensed products.

P&GP will fund any clinical development costs and will be responsible for any regulatory filings and marketing applications associated with the licensed products, as applicable.

Noven successfully formulated the licensed testosterone patch using its patented DOT Matrix transdermal delivery technology pursuant to a development agreement between Noven and P&GP established in 2003.

Noven's DOT Matrix transdermal drug delivery platform is a diffusion-based drug-in-adhesive patch technology that can often deliver more drug through a smaller patch area than competitive patches, without using irritating skin permeation enhancers, and without compromising adhesion.